ABT-888 (Dihydrochloride), 25 mg

Poly(ADP-ribose) polymerase (PARP) inhibition is central to DNA damage response research, particularly in studies of synthetic lethality in homologous recombination-deficient cancer models. This 25 mg unit of ABT-888 dihydrochloride from STEMCELL Technologies provides a potent, orally bioavailable small-molecule inhibitor of PARP-1 and PARP-2 (also known as Veliparib), supplied as the dihydrochloride salt for improved aqueous solubility in laboratory workflows.

The compound blocks PARP catalytic activity and traps PARP-DNA complexes at sites of single-strand breaks, preventing repair and forcing accumulation of toxic double-strand breaks during replication. This mechanism makes the inhibitor valuable for sensitizing BRCA1/2-mutant breast and ovarian cell lines to temozolomide, cisplatin, carboplatin, and ionizing radiation in combination studies. Researchers typically employ working concentrations between 10 nM and 10 µM across cell culture panels, with dosing optimized per cell line and assay endpoint.

For handling, the solid should be stored desiccated at -20 °C, protected from light, with freeze-thaw cycles minimized to preserve inhibitor potency. Stocks dissolved in DMSO or sterile water remain stable when aliquoted and refrigerated. STEMCELL Technologies provides each vial with supporting quality documentation, enabling reproducible DNA damage response, homologous recombination, and chemosensitization experiments.